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Na+-K+-ATPaseAutosomal dominant polycystic kidney disease (ADPKD) is the most frequent inherited nephropathy. The
development and enlargement of cysts in ADPKD requires tubular cell proliferation, abnormalities in the
extracellular matrix and transepithelial ﬂuid secretion. Multiple studies have suggested that ﬂuid secretion
across ADPKD cyst-lining cells is driven by the transepithelial secretion of chloride, mediated by the apical
CFTR channel and speciﬁc basolateral transporters. The whole secretory process is stimulated by increased
levels of cAMP in the cells, probably reﬂecting modiﬁcations in the intracellular calcium homeostasis and
abnormal stimulation of the vasopressin V2 receptor. This review will focus on the pathophysiology of ﬂuid
secretion in ADPKD cysts, starting with classic, morphological and physiological studies that were followed by
investigations of the molecular mechanisms involved and therapeutic trials targeting these pathways in
cellular and animal models and ADPKD patients. This article is part of a Special Issue entitled: Polycystic
Kidney Disease.stic Kidney Disease.
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Autosomal dominant polycystic kidney disease (ADPKD) is the
most frequent inherited nephropathy, with a prevalence ranging from
1:400 to 1:1000. Mutations in two genes, PKD1 and PKD2, have been
associated with ADPKD. Mutations in PKD1 account for ~85% of the
affected families, and they cause a renal disease that progresses more
rapidly than in PKD2 families. PKD1 and PKD2 encode integral
membrane proteins, polycystin-1 (PC-1) and polycystin-2 (PC-2)
respectively [1].
The polycystins 1 and 2 constitute a subfamily of transient receptor
potential channels, namely TRPP [2]. Polycystin-1 has 11 transmem-
brane domains, a short cytoplasmic tail and a large extracellular
region and probably functions as a receptor and/or and adhesion
molecule. The C-terminal portion interacts through a coil-coiled
domain with PC-2, G-proteins and cytoskeletal proteins. Polycystin-1
localizes to the primary cilium that projects into the lumen, and to
structures involved in cell-cell contacts such as tight junctions,
adherens junctions, desmosomes and focal adhesions [3, for review].
PC-1 forms a complex with E-cadherin and α-, β- and γ-catenins,which could regulate the mechanical strength of the adhesion and act
as amatrix sensor [4–6]. Polycystin-2 is a non-selective cation channel
capable of transporting calcium ions, predominantly localized to the
endoplasmic reticulum (ER) but also to the plasma membrane,
primary cilium and mitotic spindles in dividing cells [7]. Interactions
with PC-1 and adaptor proteins control the trafﬁcking and localization
of PC-2 to the plasma membrane [8].
The best-characterized function of polycystins is the regulation of
calcium homeostasis and signalling. The polycystin complex is thought
to act as a mechanosensory calcium channel in the primary cilium, a
protrusion on the apical surface of kidney epithelial cells involved in
ﬂow-sensing and other critical processes such as signalling, polarity, cell
proliferation and differentiation [9]. Mechanical or ﬂow-induced
bending of the primary cilium leads to a Ca2+-inﬂux through PC-2
which in turn activates a calcium-induced Ca2+-release via ryanodine
receptors (RyR) in the ER, overall increasing intracellular Ca2+-
concentration ([Ca2+]i) [10]. Intracellular Ca2+ homeostasis and
signalling is important for regulation of a variety of cellular functions,
including cell volume regulation, ion and ﬂuid transport, differentiation
and cell proliferation [3,11]. Functional loss of either PC-1 or PC-2
disrupts intracellular Ca2+ regulation by decreased Ca2+-inﬂux,
reduction of ER stores and store-operated Ca2+ entry, leading to a
decrease in [Ca2+]i and an abnormal cell proliferation phenotype [3].
In addition to epithelial cells, both PC-1 and PC-2 are expressed in
vascular smoothmuscle cells and endothelial cells ofmost blood vessels,
which is relevant when knowing that ADPKD patients often present
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develop various types of vascular lesions including intracranial
aneurysms [1]. Recent studies [reviewed in Ref. 12] suggest that ﬂow
stimulation activates the polycystin complex in the primary cilium of
endothelial cells, leading to increased intracellular Ca2+ concentration,
release of nitric oxide and vasodilation. Furthermore, the group of
Honoré recently demonstrated that the polycystins (and more exactly,
the PC-1/PC-2 ratio) regulate the opening of non-selective stretch-
activated ion channels (SACs) that mediate the myogenic response of
blood vessels, i.e. the pressure sensing by arterial myocytes [13]. The
potential link between amodiﬁed SAC activity resulting frommutations
in PKD1 or PKD2 and the propensity for arterial lesions in patients with
ADPKD remains to be demonstrated.
The ADPKD cysts derive from 1% to 3% of the nephrons. They
potentially involve all nephron segments, although an important
fraction of the cysts is derived from the collecting ducts [14,15].
Although the cysts already exist in utero, they usually become
clinically detectable only in the young adult [16]. The prospective
follow-up of ADPKD patients with yearly magnetic resonance imaging
examinations has established that cysts increase at a stable rate of ~5%
per year [17]. Total kidney volume and cyst volume progression are
the strongest predictors of renal function decline in ADPKD [18], with
slow progression to end-stage renal failure in about 50% of patients.
ADPKD is responsible for 4% to 10% of the patients requiring a renal
replacement therapy.
A large body of evidence suggests that cyst development and
enlargement in ADPKD requires tubular cell proliferation, abnor-
malities in the extracellular matrix and a net, transepithelial ﬂuid
secretion (i.e. directed towards the cyst lumen). Since the cysts are
anatomically separated from the tubule from which they derive [19],
the intracystic ﬂuid does not originate from the glomerular ﬁltrate
but rather from a transepithelial ﬂuid secretion. The existence of
such a ﬂuid secretion is in itself a major anomaly as the normal
function of the different tubular segments is to reabsorb more than
99% of the glomerular ﬁltrate. In this article, we will review the data
substantiating the pathophysiology of ﬂuid secretion in ADPKD
cysts, starting with macroscopic studies (cyst ﬂuid composition;
electrical properties of cystic epithelia) that were followed by the
molecular characterization of the transport mechanisms involved
and therapeutic trials targeting these pathways in animal models
and ADPKD patients.Table 1
Fluid composition, ultrastructural features and electrical parameters in ADPKD cysts.
Type of cyst
No-gradient
Composition
Na+ (mmol/L) 138 (129–150)
K+ (mmol/L) 5.1 (4.6–8.6)
Ammonia (μmol/L) 0
Total Ca2+ (mmol/L) 2.0 (1.4–3.7)
Mg2+ (mmol/L) 1.5 (1.2–2.6)
Cl− (mmol/L) 96 (88–104)
Glucose (mmol/L) 5.8 (2.6–8.8)
pH 7.4
Osmolality (mOsm/kg H2O2) 290 (264–336)
Osmolal gap 0
Ultrastructural characteristics
Length of junctions (μm) b500
Electrical parameters
R (Ω/cm2) 31 (11–50)
V (mV) 0.1 (−0.4 to +0.6)
I (μA/cm2) 7 (−6 to +11)
I/V inhibition by amiloride –
Abbreviations: R, Transepithelial ohmic resistance; V, Transepithelial potential difference; I
Mean values (range) are shown (adapted from Refs. 21,23,25,26).
Plasma reference values are shown for comparison with the regular ﬁltrate: a, fasting; b, ar2. Cyst ﬂuid composition
The pioneering work of P.P. Lambert in the 1940s has established
that cysts in ADPKD arise as saccular expansions of a tubule from
which they later separate—to become totally independent as they
expand in volume [20]. Initially, intracystic tubular ﬂuid can thus be
considered as a plasma ultraﬁltrate. However, as the cysts lose their
connection with their parent tubular segment, intracystic ﬂuid
accumulation necessarily reﬂects water and solutes secretion by the
cystic epithelium itself. As cysts may arise from any tubular segment
of the nephron, cyst ﬂuid composition should somehow reﬂect its
tubular origin. Gardner classiﬁed ADPKD cysts into two categories on
the basis of a Na+ concentration above or below 100 mmol/l [21]. As
shown in Table 1, both types of cysts also differ in the length of their
junctional complexes [22]. Cysts with a low Na+ concentration
(“gradient cysts”) are capable of maintaining a transepithelial ionic
gradient, suggesting that they derive from the tight, distal nephron
segments. Conversely, cysts exhibiting a high Na+ concentration
nearly equal to plasma (“no gradient cysts”) most probably derive
from the leaky, proximal tubule [23]. Although osmolality was found to
be similar inboth types of cysts, thegradient cystswere characterizedby
a signiﬁcant osmolal gap which could correspond to unmeasured
organic anions (i.e. organic phosphates) or to osmoles normally made
by the cells of the ascending limb of Henle (i.e. sorbitol, betaine) [24].
The presence of proteins within the cystic ﬂuid could result from
epithelial cells desquamation associated with ischemia, partial necrosis
or proliferation [24].
3. Electrical properties of cystic epithelia
Epithelia can be classiﬁed on the basis of the permeability of their
junctional complexes, a parameter that determines the transepithelial
ohmic resistance. Only epithelia possessing true “tight” junctions are
able to maintain a sizeable transepithelial potential difference and
ionic gradient. Perrone [25] was the ﬁrst to measure the electrical
parameters of ADPKD cystic epithelia mounted in Ussing chambers
(Table 1). “No gradient” cysts showed a low transepithelial resistance
and an almost null transepithelial potential difference. By contrast,
“gradient” cysts exhibit a transepithelial resistance similar to tight
epithelia and a sizeable transepithelial potential difference that could
be short-circuited. The short-circuit current (15–20 μA/cm2) and thePlasma
Gradient (Ref. values)
4.8 (3–75) 135–145
25.3 (5.1–58) 3.5–5.0
9.4 (3.2–15.5) 10–35
1.0 (0.25–1.95) 2.1–2.5
7.4 (2.7–12.2) 0.6–0.8
18.3 (8.7–27.9) 95–105
14.1 (7.3–32.9) 4.0–6.0a
5.2 7.35–7.45b
293 (193–313) 275–295
97 ~0
N500
208 (153–332)
5 (2.6–7.2)
19 (16–22)
++
, short-circuit current intensity. Amiloride (10 μmol/L) is added on the apical side.
terial blood.
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apical amiloride, indicating that the current reﬂects Na+ reabsorption.
Radioactive ﬂux measurements conﬁrmed a net Na+ reabsorption by
“gradient” cysts epithelia [25,26].
In 1991, Wilson et al. studied bilateral 22Na ﬂuxes through
monolayers of cystic cells grown on ﬁlters [27] and observed a net
secretory ﬂux of 22Na into the cyst lumen that was inhibited by
ouabain (a cardiotonic steroid inhibitor of Na+-K+-ATPase) from the
apical side. Of note, these ﬂuxes were obtained in the presence of a
spontaneous transepithelial potential difference, so that the observed
22Na secretion could be driven by a primary Cl− secretion. A primary
secretion of Na+ should yield a transepithelial potential difference,
lumen positive, but this parameter was not available [27].
Most ﬂuid secretion processes are secondary to the secretion of Cl−,
as exempliﬁed for the ﬂuid secretion of the cryptic small intestine
epithelium and the secretory diarrhea induced by cholera toxin [28].
Evaluating the determinants of cyst ﬂuid secretion, the group of
Grantham proposed a similar sequence of events in ADPKD, based on
elegant studies performed on cysts in situ and on cystic cells cultured as
conﬂuent monolayers and in three dimensions on collagen matrix.
Electrical data, recorded in Ussing chambers, showed (i) the existence,
in the basal state, of a transepithelial potential difference lumen
negative, implying a net secretion of anions or a net reabsorption of
cations; (ii) an increase of luminal electronegativity after the addition of
forskolin (an adenylate cyclase agonist stimulating the production of
cAMP) [29]. Several secretagogues have been identiﬁed in human
ADPKD cyst ﬂuid, most of which stimulate adenylyl cyclase and the
cAMP cascade, including a lipophilic, forskolin-like molecule [30,31].
4. Na+-K+-ATPase
The Na+-K+-ATPase (often referred to as the “sodium pump”) is an
ubiquitous enzyme discovered by J.C. Skou [32], who was awarded the
1997 Nobel Prize in Chemistry. The fundamental role of the Na+-K+-
ATPase is to generate and maintain Na+ and K+ gradients which in turn
control cellmembrane potential difference and cell volume. TheNa+-K+-
ATPase is made of the α subunit which catalyzes Na+ and K+
translocation, hydrolyzes ATP and binds ouabain; the β subunit, which
plays a role in the enzyme maturation and membrane targeting; and a
γ subunit (FXYD2) which belongs to the family of FXYD proteins that
modulate the Na+-K+-ATPase activity in a tissue-speciﬁc way [33]. Of
interest, Zatti et al. demonstrated that the C-terminal tail of PC-1 interacts
with theα-subunit of the Na+-K+-ATPase, and that this interaction could
regulate the Na+-K+-ATPase activity in the kidney [34].
In most epithelia, with the exception of the retinal epithelium and
the choroid plexus, Na+-K+-ATPase is localized within the basolateral
plasma membrane domain. By contrast, immunolocalization studies
performed by Wilson et al. showed that Na+-K+-ATPase was localized
exclusively in the apical plasma membrane domain of cystic epithelial
cells, potentially accounting for the 22Na net ﬂux aswell as the action of
ouabain from the apical side of the cyst-lining cells reported by the same
authors [27]. The further demonstration of the β2 subunit within these
apical complexes led to propose that the mispolarization of Na+-K+-
ATPase was related to the formation ofα1β2 complexes in ADPKD cells
[35]. Since the β2 subunit is normally expressed in the fetal kidney,
where it has been implicated in apical targeting of Na+-K+-ATPase in
the ureteral bud, its abnormal expression in the ADPKD cystic
epithelium could reﬂect cellular dedifferentiation and participate in
the driving force for cyst ﬂuid accumulation [35].
The view that the apical localization of Na+-K+-ATPase in the cystic
epithelium plays a role in cyst ﬂuid accumulation has been strongly
debated. Such a distribution cannot explain the luminal electronegativity
or the lack of effect of apical ouabain reported by others [25,36]. In a study
designed to minimize ischemic damage, Carone et al. observed an apical
Na+-K+-ATPase polarization in 25% of the ADPKD cystic cells, whereas
most cystic cells exhibited a normal basolateral Na+-K+-ATPase and anormal capacity for apical endocytosis [37]. In contrast, Brill et al. localized
Na+-K+-ATPasewithin the basolateral membrane of cultured cystic cells,
although there was some heterogeneity in this expression [38]. The
observations of Wilson et al. might thus reﬂect cell dedifferentiation,
perhaps related to culture conditions, or a loss of polarity caused by ATP
depletion or tissue ischemia [39]. Further studies in MDCK cells stably
expressing the β1 and β2 subunits demonstrated a strictly basolateral
targeting under normal growth conditions, whereas inclusion of butyrate
in the growthmedium led to the upregulation ofβ1- andβ2-subunits and
their appearance at the apical surface [40]. On the other hand, Nguyen
et al. demonstrated that nanomolar concentrations of ouabain induced
proliferation of ADPKD cells at a much higher rate than normal human
kidney cells, via the activation of theMEK-ERK pathway. The ADPKD cells
showed a higher afﬁnity for ouabain, which was not due to differences in
the α1/β1 subunits but could involve the γ subunit which was
upregulated in these cells [41].
The possibility of apical mistargeting of the Na+-K+-ATPase has been
investigated in differentmodels of polycystic kidney disease. An increased
activity of the Na+-K+-ATPase, together with a transient increase in the
apical expression of α1 and β1 subunits have been demonstrated in the
early stages of cyst development in the cpkmouse, a model of autosomal
recessive polycystic kidney disease [42]. In the SBM transgenic mouse
model of ADPKD, in which cyst development is related to a proliferation
induced by the targeted expression of the c-myc proto-oncogene in the
renal epithelium, apical labeling for Na+-K+-ATPase was observed in the
early stages of cyst development of the young animal, to signiﬁcantly
decrease in the adult stage [43]. In contrast, a detailed histopathological
analysis of renal cystic epithelia failed to show amispolarization of theα1
subunit in the Pkd2WS25/- mouse model, which recapitulates cystogenesis
in human ADPKD [44]. More recently, an increased expression of the β2
subunit in cystic kidneys was reported in a homozygous Pkd1 mutant
mouse model [45], but no apical misolocalization could be detected.
5. Chloride secretion and CFTR
Although the renal tubule epithelium reabsorbs more than 99% of the
glomerularﬁltrate, early studiesperformed in the isolated rabbit proximal
tubule [46] have shown that the renal tubule epithelium possesses a
capacity for ﬂuid secretion. In particular, an apical conductance for Cl−,
stimulated by cAMP, has been evidenced in several epithelia [47–49] and
cell lines derived from the distal nephron [50,51].
Fluid secretion at the level of ADPKD cystic epithelium was ﬁrst
suggested by the fact that, after drainage, a renal cyst quickly ﬁlls
again [52]. The demonstration of in vivo ﬂuid secretion by ADPKD
cysts following injection of secretin, an adenylyl cyclase agonist, was
provided by Everson et al. [53]. Fluid secretion by cyst walls was
conﬁrmed in vitro and ex vivo by numerous investigations from
Grantham and colleagues [29,54]. By analogy with other epithelia,
Grantham then suggested that Cl− secretion was the driving force for
ﬂuid secretion in ADPKD cysts [29]. The key role of Cl− was
demonstrated by studying in parallel currents and ﬂuid secretion in
monolayers of ADPKD cyst cells [36,55]. These studies conﬁrmed that
ﬂuid secretion was stimulated by adenylyl cyclase agonists, and also
by the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine
(IBMX) or by 8-Br-cAMP, a form of cAMP insensitive to hydrolysis
by phosphodiesterase. Furthermore, the ﬂuid secretion induced by
forskolin was accompanied by an increase in luminal electronegativ-
ity. These effects were inhibited by the addition of bumetanide or the
isotonic replacement of Cl− in the basolateral medium, or by the Cl−
channel inhibitor diphenylamine-2-carboxylate (DPC) on the apical
side [36,55].
The analogy between the properties of the ADPKD cystic epithelium
and those of other secretory epithelia suggested that the CFTR (“cystic
ﬁbrosis transmembrane conductance regulator”) channel could be the
molecular counterpart of the cAMP-stimulated Cl− secretion in ADPKD
cysts. Mutations in the CFTR (or ABCC7) gene CFTR cause cystic ﬁbrosis,
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CFTRprotein is amember of theATP-binding cassette (ABC) superfamily
of integral membrane transporters [56]. The protein is organized
symmetrically in two transmembrane domains (TMD1 and TMD2)
and two nucleotide binding domains (NBD1 and NBD2), separated by a
large, polar, regulatory (R) domain unique within the ABC family. CFTR
is regulated by cAMP-dependent phosphorylation of the R domain via
PKA, followed by ATP-dependent gating events initiated by ATP binding
to the cytoplasmic nucleotide-binding domains and resulting in
transepithelial Cl− transport [56]. Multiple interactions regulate CFTR-
mediated Cl− secretion by modulating both its channel activity and its
intracellular trafﬁcking [57]. CFTR interacts functionally with other
channels, including the outwardly rectifying Cl− channels (ORCC) and
the Na+ channel ENaC, and it participates in exocytosis and the
formation of macromolecular complexes at the plasmamembrane [58].
Several studies have demonstrated that CFTR is signiﬁcantly
expressed in the mammalian kidney [59–61]. In mouse kidney, CFTR
is mainly expressed in the apical area of PT cells, with a subcellular
distribution compatible with endosomes [61]. In human kidney, CFTR
protein expression was detected in the PT, in addition to the thin
limbs of Henle's loop, distal tubules and collecting ducts [59,60]. The
expression of CFTR has been evidenced in primary cultures of ADPKD
cells and ADPKD kidney extracts, with a staining pattern suggesting a
localization in the apical membrane of cyst-lining cells [62]. Selective
Cl− currents were recorded in cultured ADPKD cyst cells, stimulated
by forskolin and a permeant analogue of cAMP, and totally blocked by
the CFTR blocker DPC [62]. A signiﬁcant heterogeneity in CFTR
expression has been observed [38,62,63], which could suggest that
some cells are too dedifferentiated to express the protein and that a
subset of cyst-lining cells with functional CFTR is sufﬁcient to drive
ﬂuid secretion. Alternatively, other types of Cl− channels or
transporters might be implicated in ﬂuid secretion.
The role of CFTR in mediating Cl− and ﬂuid secretion in ADPKD
was ﬁrst substantiated in vitro by showing that the forskolin-
stimulated ﬂuid secretion was dramatically reduced after incubation
of monolayers of ADPKD cells with an antisense oligonucleotide
against human CFTR [63]. The discovery of various types of speciﬁc
CFTR inhibitors by the group of Verkman provided additional
evidence for the essential role of CFTR in vitro and in vivo. The
thiazolidinone inhibitor CFTRinh-172, which stabilizes the channel
closed state, inhibited cyst growth in MDCK cells [49] and in
metanephric kidney organ culture [64]. A further screening allowed
to show that two CFTR inhibitors (tetrazolo-CFTRinh-172 and the
phenyl-derived glycine hydrazide Ph-GlyH-101) suppressed cyst
growth in MDCK cells without affecting cell proliferation; inhibited
cyst number and growth in a cAMP-stimulated embryonic kidney cyst
model; and, remarkably, slowed kidney enlargement and cyst growth
and preserved renal function in a neonatal, kidney-speciﬁc Pkd1
knock-out model (Pkd1ﬂox/−:Ksp-Cre mice) [65]. These data suggest a
potential therapeutic role for CFTR inhibitors to slow cyst ﬂuid
accumulation in ADPKD (Fig. 1). Since these inhibitors concentrate in
the kidney and show little accumulation in the lung, and because
inactivation of N90% of CFTR is necessary to affect lung function, their
use should not be complicated by a cystic-ﬁbrosis like pulmonary
disease [65]. Of note, a milder cystic phenotype has been reported in
three patients with ADPKD coexisting with cystic ﬁbrosis, as
compared to siblings with ADPKD alone [66,67]. This protective effect
has not been conﬁrmed in a subsequent report, which evidenced the
continuous expression of apical CFTR in a large fraction of ADPKD
cysts [68]. The protective role of CFTR mutations in ADPKD may be
related to the nature of the mutation (N1000 documented in cystic
ﬁbrosis) and the residual expression of the mutated CFTR protein in
cyst-lining epithelial cells [68].
There is increasing evidence that the epithelial cells lining various
nephron segments can release ATP (and adenosine) into the lumenunder
the inﬂuenceofmechanical or chemical stimuli, followedbyautocrineandparacrine signaling via various types of purinergic receptors expressed in
the apical membrane of the cells. In turn, this “purinergic signaling
microenvironment” plays an important role in the regulation of ion
transport in various nephron segments [69]. Several investigators
documented thepresenceof suchpurinergic signaling in theencapsulated
cystsofADPKD,where it could stimulate thesecretionofCl−, and thus cyst
growth, through Ca2+-activated chloride channels [70,71].
6. Basolateral chloride transport
The search for themechanisminvolved in thebasolateralCl−uptake in
ADPKD cyst-lining cells was guided by the effect of the loop diuretic
bumetanide, which reduces rapidly the luminal electronegativity and
decreases ﬂuid secretion when applied at the basolateral pole of ADPKD
monolayers [36]. Loop diuretics speciﬁcally inhibit a family of cotran-
sporters (SLC12A1 and SLC12A2) that transport Na+, K+ and Cl− in an
electroneutral way [72]. In addition to their role in cell volume regulation,
these cotransporters represent a pathway for Cl− entrance in epithelia
involved in the reabsorption (ascending limb of the loop of Henle) or
secretion (salivary glands, respiratory tract) of chloride. The SLC12A1
isoform (also calledNKCC2) is exclusively located in the apicalmembrane
of the thick ascending limb of Henle's loop, whereas the SLC12A2 isoform
(also named NKCC1) is ubiquitous expressed in both the basolateral pole
of Cl−-secreting epithelia and non-epithelial cells. Lebeau et al. investi-
gated the expression of NKCC1 and CFTR in ADPKD kidneys and cultured
ADPKD cells [73]. Immunoblotting and immunoprecipitation detected
NKCC1 in ADPKD cells and kidney extracts. Immunostaining located
NKCC1 in one-third of ADPKD cysts, with a pattern of basolateral
reactivity. Staining of serial sections showed that cysts positive for NKCC1
also stained for CFTR. The fact that most CFTR-positive ADPKD cysts also
express NKCC1 suggests that transepithelial Cl− secretion in ADPKD
involves molecular mechanisms similar to secretory epithelia. This
conclusion has been supported by the demonstration of NKCC1 in the
basolateral membranes of advanced cystic lesions in the Pkd2WS25/−
mouse model [44]. Since the activity of NKCC1 is critical for maintaining
the intracellular concentration of Cl−, it would be interesting to evaluate
the state of the WNK (with no lysine) serine-threonine kinases and their
key downstream substrates SPAK (Ste20/sps1-related proline/alanine-
rich kinase) and OSR1 (oxidative-stress responsive kinase 1) in the
ADPKD cyst-lining epithelia [74]. Targeting NKCC1 with loop diuretics
could theoretically be envisaged, but the efﬁcacy (remaining blood
supply) and safety (risk of hypokalemia) of such an approach remains
very uncertain. Of note, Lebeau et al. demonstrated that the Cl−–HCO3−
anion exchanger type I (AE1), which normally operates in the basolateral
membrane of α-type intercalated cells in the collecting ducts, is also
expressed at thebasolateral pole of CFTR-positiveADPKDcysts that donot
express NKCC1. Accordingly, AE1 might be an alternative basolateral
pathway for Cl− in a subpopulation of cysts [44,73].
The sustained activity of NKCC1 in the basolateral membrane of cyst
epithelial cells requires basolateral recycling of K+ andNa+, aswell as the
maintenance of a hyperpolarized membrane potential (Fig. 1). In a series
of elegant studies, Albaqumi and colleagues recently demonstrated the
role of the Ca2+-activated potassium channel KCa3.1 in mediating the
efﬂux of K+ andmaintaining a relatively negative intracellularmembrane
potential that drives the apical Cl− secretion by CFTR in monolayers of
kidney cells derived from patients with ADPKD [75]. The clotrimazole
analogueTRAM-34,which speciﬁcally inhibits KCa3.1, inhibited forskolin-
stimulatedCl− secretionacross themonolayers (without affectingCFTRor
other apical Cl− channels), and inhibited cyst formation and enlargement
in collagen matrix. It must be noted that such des-imidazolyl trityl
derivatives are already used in phase 3 clinical trials to block KCa3.1 in
sickle cell disease without side-effects, which opens the way for testing
the effect of these compounds in animal models of ADPKD [75,76]. Both
cAMP and PKA may activate KCa3.1 channels, which is relevant when
considering the importance of cAMP in the pathogenesis of ADPKD (see
below).
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Fig. 1.Mechanisms of ﬂuid secretion in ADPKD cyst-lining epithelial cells. Model of the transporters and channels involved in ﬂuid accumulation in the lumen of ADPKD cysts. The apical
and basolateral poles of the cell are delineated by tight junctions. The transepithelial secretion of Cl− is mediated by the basolateral Na+-K+-2Cl− cotransporter NKCC1 and apical Cl−
channels including theprotein kinaseA (PKA)-stimulatedCFTR andCa2+-activatedCl− channels (CACC). This transepithelial pathway is stimulatedbyan increased concentrationof cAMP,
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and stimulation of the vasopressin V2 receptor (V2R) pathway. The apical CACC are stimulated by an autocrine/paracrine purinergic signalingmediated by purinergic receptors (P2X and
P2Y). The activity of NKCC1 requires the recycling of K+ via the basolateral potassium channel KCa3.1 and that of Na+ via the Na+-K+-ATPase. The net secretion of Cl− induces a
transepithelial movement of Na+ (electric coupling) and water (osmotic coupling). The presence of water channels (AQPs) in some cysts may facilitate transcellular water transport.
Disruption of the complex formed by polycystin-1 (PC-1) and polycystin-2 (PC-2) is probably involved in the alteration of intracellular Ca2+ levels. The drugs targeting these transport
pathways that are currently investigated in vivo and/or in vitro are indicated in blue boxes. For details, see text. Additional abbreviations: IP3R, inositol trisphosphate receptor; RyR,
ryanodine receptor; SERCA, sarco(endo)plasmic reticulum Ca2+-ATPase; SST2, somatostatin receptor. (Adapted from Refs. 3,70,76,97).
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Adefect in the urine concentration ability has long been established in
ADPKD patients, including children, even before the onset of renal failure
[77–80]. The severityof theurine concentratingdefect hasbeen correlated
to renal and cyst volume [79,80]. In parallel, higher plasma levels of
vasopressinweredetected inhypertensiveADPKDpatients aswell as after
hypertonic saline loading [81] and, in one cohort, at baseline [82].
Recently, Meijer et al. showed that plasma copeptin concentration, a
surrogate marker of endogenous vasopressin levels, was associated with
variousmarkers of disease severity in a cross-sectional analysis of a cohort
of 102 ADPKD patients [83]. The vasopressin V2 receptor (V2R) is the
major regulator of adenylyl cyclase activity and source of cAMP
production in the principal cells lining the collecting ducts. Increased
levels of cAMP and cAMP-target genes have been observed in the cystic
kidneys of various rodent models [3]. The increased cAMP levels may be
the direct consequence of decreased intracellular Ca2+ levels caused by
mutations in PC-1 and PC-2, via the downregulation of phosphodiesterase
PDE and stimulation of the Ca2+-inhibitable adenylyl cyclase 6 [3]. In turn,
the increasedproductionof cAMP stimulates the proliferation and growth
ofADPKDcells anddrives Cl− andﬂuid secretionvia PKA-stimulatedCFTR
and, potentially, the basolateral channel KCa3.1 (Fig. 1).
The importance of the V2R-cAMP pathway has been demonstrated
by the spectacular effects of V2R antagonists on lowering renal cAMP
levels and slowing renal cyst development in various models of PKD
and nephronophthisis (cpk mouse, PCK rat, Pkd2WS25/- mouse, pcy
mouse) [3, for review]. Nagao et al. demonstrated that vasopressin
suppression by high water intake decreased cyst and renal volumes in
PCK rats, with a reduced activity of cAMP-dependent B-Raf/MEK/ERK
pathway [84]. Furthermore, the deletion of vasopressin in these PCKrats (by crossing them to Brattleboro rats) led to lower renal cAMP
levels and an almost complete inhibition of cystogenesis, whereas
administration of dDAVP recovered the cystic phenotype in the PCK x
Brattleboro rats [85]. These results support the importance of cAMP in
the pathogenesis of polycystic kidney disease and conﬁrm that
targeting the vasopressin-V2R axis effectively inhibits cystogenesis.
Based on these animal studies, a phase III clinical trial investigating the
effect of the highly-selective V2R antagonist Tolvaptan (OPC-41061) in
ADPKD patients is ongoing. Of note, V2R antagonists have no effect on
liver cysts because V2 receptors are not expressed in the liver.
A distinct approach to lower cAMP levels is to mimic the action of
somatostatin on the Gi-coupled SST2 receptors which induce acute
desensitization of adenylyl cyclase coupling [86]. Octreotide, a long-acting
somatostatin analogue halted the cystic progression in the liver and
kidney of PCK rats [87,88] and slowed renal cystic progression in a
preliminary study performed in ADPKD patients [89]. These encouraging
results have been conﬁrmed in clinical trials showing that octreotide and
lanreotide signiﬁcantly inhibit the progressive increase in liver volume
and total kidney volume, with an acceptable safety proﬁle [88,90].
8. Aquaporins
The long quest for the molecular identity of the water pore ended
with the discovery of aquaporin-1 (AQP1) by Agre, who obtained the
2003 Nobel Prize in Chemistry [91, for review]. Antibodies raised
against the protein puriﬁed from red blood cells showed its
localization in the proximal tubules and the descending thin limbs
of the loop of Henle, i.e. the very tubular segments characterized by a
high intrinsic water permeability. AQP1, the archetypal water
channel, facilitates the selective transport of 3 billions of water
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(AQP0 to AQP12) have been identiﬁed in mammals, with speciﬁc
expression patterns and distinct roles in given tissues and cells. With
the exception of AQP2, whose membrane expression is regulated by
the antidiuretic hormone vasopressin, most AQPs are constitutively
expressed in the plasma membrane. Aquaporins play speciﬁc roles in
epithelial cells lining various segments of the kidney [92]. The apical
and basolateral distribution of AQP1 in proximal tubule cells allows a
massive, transcellular reabsorption of water driven by a minimal
osmotic gradient. The AQP1 channels localized in the cells lining the
thin descending limb of Henle's loop allow a rapid osmotic
equilibrium with the interstitium, an essential step for the counter-
current mechanism. In contrast, AQP2 is expressed only in the
principal cells of the collecting ducts (apical membrane and
intracellular vesicles). The increased water permeability induced by
vasopressin in that segment corresponds to the phosphorylation and
rapid insertion of AQP2-containing vesicles in the apical plasma
membrane of the principal cells. Vasopressin exerts also a long-term
effect on AQP2 expression via a cAMP-responsive element located in
the 5′ region of the AQP2 gene. Two other types of aquaporins have
been identiﬁed in the basolateral membrane of principal cells of the
collecting ducts: AQP3 (also permeable to glycerol), and AQP4 (the
only aquaporin that is not inhibited by mercurials) [92,93].
In addition to the Cl− secretion, it was assumed that water
channels could also play a role in the abnormal ﬂuid transport in
ADPKD by facilitating water transport across cystic epithelia.
Bachinski et al. located AQP1 in a majority (~70%) of cysts of proximal
tubule origin (gp330 positive) in human ADPKD kidneys, whereas a
minority of the cysts (8%), negative for AQP1 and gp330, expressed
AQP2 [94]. Devuyst et al. conﬁrmed the selective and mutually
exclusive expression of AQP1 and AQP2 in various stages of ADPKD
[15]. The distribution of AQP1 and AQP2 was maintained in the early
stages of ADPKD, when normal tubules coexist with cysts. In end-
stage ADPKD, two-thirds of the cysts expressed either AQP1 or AQP2,
but the two water channels never colocalized in the same cyst. Of
note, the proportion of AQP2-positive cysts signiﬁcantly increased
with cyst size, suggesting a role for vasopressin in cyst enlargement
[15]. Based on the simultaneous expression of AQP2 and AQP3 in the
collecting ducts, Hayashi et al. showed that approximately 30% of the
cysts derived from collecting ducts [95]. The preservation of a speciﬁc
AQP expression in cystic cells may suggests indeed that, next to Cl−
secretion, channel-mediated water permeability might be implicated
in ﬂuid secretion. The fact that one-third of the cysts do not express
AQP1 or AQP2 [15] suggests that cysts originate from segments that
do not express aquaporins, such as the thick ascending limb of the
loop or the distal convoluted tubule. This hypothesis has been
conﬁrmed by subsequent studies performed in the Pkd2WS25/−
mouse model [44] and, more recently, in Pkd1-null embryos [96].
Recently, Aharabi et al. showed that the complex chain of events
mediating AQP2 trafﬁcking in the collecting duct was modiﬁed by
Pkd1 haploinsufﬁciency in mouse [97]. Reduced Pkd1 gene dosage
resulted in inappropriate antidiuresis and positive water balance,
reﬂecting decreased intracellular calcium levels with lowered RhoA
activity and recruitment of AQP2 in the apical membrane of CD
principal cells, and inappropriate expression of AVP in the brain.
These data emphasize the potential role of PC-1 dosage in the
regulation of vasopressin signaling and AQP2 trafﬁcking in the
collecting duct [97].
It must be noted that mice that lack AQP11, which is localized in
the ER of proximal tubule cells, died shortly after birth from massive
polycystic kidney disease derived from proximal tubules [98]. In that
peculiar case, it is important to mention that AQP11 is not expressed
in the plasma membrane and therefore does not contribute to
transepithelial water transport. Instead, the cystic phenotype of these
KOmicemay be due to the dysfunction of PT cells potentially linked to
ER stress and vacuolization [98].9. Conclusions and perspectives
The multiple lines of evidence summarized above have delineated
mechanisms involved in the accumulation of ﬂuid in ADPKD cysts. As
summarized in Fig. 1, ﬂuid secretion is driven by the transepithelial
secretionofCl−,mediatedby systemsoperating in series at the level of the
two cellular poles : the basolateral NKCC1 cotransporter is responsible for
Cl− entry into the cell, whereas apical Cl− channels including CFTR allow
the accumulation of Cl− within the cyst lumen. The whole secretory
process is stimulated by cAMP and by autocrine and paracrine purinergic
signaling. The activity of NKCC1 requires the basolateral recycling of K+
via the KCa3.1 and of Na+ via the Na+-K+-ATPase. The former also plays
an important role in maintaining a negative intracellular membrane
potential that provides the electrochemical driving force for apical Cl−
secretion. The luminal accumulation of Cl− drives Na+ transport by
electrical coupling. Driven by the osmotic gradient, water crosses the
epitheliumand accumulates into the cyst lumen. Thismovement ofwater
is probably facilitated by aquaporins in a subset of cysts. This model is
certainly not unique, since ADPKD typically involves different tubular
segments and therefore a diversity of transport systems.
Since cyst expansion is amajor factor for the progressive deterioration
and loss of renal function in ADPKD [17,18], therapies targeting ﬂuid
secretion and, thereby, cyst enlargement are of major clinical interest. To
date, the effect of vasopressin V2 receptor antagonists, somatostatin
receptor agonists and inhibitors of CFTR have been successfully tested in
animal models and/or in patients with ADPKD [1,3]. Additional targets
related to transport mechanisms include the basolateral KCa3.1 [75,76],
regulators of intracellular Ca2+ levels [99,100], molecules involved in the
regulation of CFTR [58], NKCC1 [74] or AQPs [101], and regulators of
intracellular levels of cAMP [102].
The long-term efﬁcacy and safety of successful ﬂuid transport
inhibition in patients with ADPKD remain to be established. However,
the increasing availability of selective drugs targeting transport systems
offers an alternative – or a complement – to the anti-proliferative
therapies in ADPKD.Acknowledgments
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